Skip to main content
Premium Trial:

Request an Annual Quote

David Ebsworth, James Niedel, Daniel Chelsky


Oxford Glycosciences has named David Ebsworth CEO effective July 1, 2002, the company said last week. Ebsworth will replace Michael Kranda, who is leaving the company for family reasons, the company said in March. Ebsworth most recently served as head of the worldwide pharmaceutical business group of Bayer. Prior to that, he was president of Bayer’s North American pharmaceutical division, with responsibility for all functions from research through clinical development, regulatory affairs, sales and marketing, and finance and strategy.

Venture-capital firm Sprout Group has hired former GlaxoSmithKline chief science and technology officer James Niedel, the company said last week. Niedel will be venture partner for health-care technology investments. Between 1995 and 2001, Niedel was a board member at Glaxo Wellcome, where he oversaw global R&D, information technology, and product strategy. The Sprout Group is a venture capital affiliate of Credit Suisse First Boston.

Daniel Chelsky will join Caprion Pharmaceuticals as executive vice president and chief scientific officer, the company said last week. Chelsky replaces John Bergeron as CSO, a McGill University professor and co-founder of the company who will remain affiliated with Caprion as a member of its scientific advisory board. Chelsky most recently served as president and general manager of BioSignal Packard, a division of PerkinElmer, where he oversaw the development of technology development for drug discovery and genomics research. He has also worked at Pharmacopeia, where he served as senior director of biology.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.